Oxidative Stress in Systemic Sclerosis Literature Review

Year 2012, Volume: 13 Issue: 3, 37 - 41, 01.12.2012

Şükran Erten Murat Turgay

Abstract

Etiopathogenesis of systemic sclerosis is not well-known and oxidative stress has been supposed to play a role in the endothelial damage at the initial phase of the disease. In systemic sclerosis and Raynaud phenomenon, decrease in antioxidant potential and increase in the free radicals were detected in circulation. It is necessary to show production of excess amounts of free radicals or deficiency of antioxidants to detect oxidative stress. In patients with systemic sclerosis, the etiology of decrease in the antioxidant enzymes is unknown. Changes in the intermediate metabolism of antioxidants or consumption of antioxidants caused by hypoxia which is induced by Raynaud phenomenon may be the cause. Ischemia itself, especially if it is together with hypoxia may cause tissue damage. Endothelial cell dysfunction occurs especially at early stages of the disease.

Keywords

Systemic sclerosis, oxidative stress, antioxidants

References

• Emerit I, Filipe P, Meunier P, et al. Clastogenic activity in plasma of scleroderma patients: a biomarker 2. of oxidative stress. Dermatology 1997;194:140-6.
• Solans R, Motta C, Sola R. Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis:evidence of free radical mediated-injury. Arthritis Rheum 3. 2000;43:894-900.
• Volpe A, Biasi P, Caramaschi P, et al. Levels of F2- isoprostanes in systemic sclerosis:correlation with clinical features. Rheumatology 2006;45:314-320. 4.
• Simonini G, Cerinic MM, Generini S, Zoppi M, Anichini M, Cesaretti C, Pignone A, Falcini F, Lotti T, Cagnoni M. Oxidative stress in systemic sclerosis. Molecular and Cellular Biochemistry 1999;196:85-91.
• Denton CP, Bunce TD, Dorado MB, Roberts Z, Wilson H, Howell K, Bruckdorfer KR, Black CM. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. Rheumatology 1999;38:309-15.
• Murrel DF. A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 1993;28:78-85.
• Cope KA, Solga SF, Hummers LK, et al. Abnormal exhaled ethane concentrations in scleroderma. Biomarkers 2006;11(1):70-84.
• 26.Rottoli P, Magi B, Cianti R, et al. L. Carbonylated proteins in bronchoalveoler lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Peoteomics 2005;5:2612-8.
• Sfrent-Cornateanu R, Mihai C, Stoian I, Lixandru D, Bara C, Moldoveanu E. Antioxidant defense capacity in scleroderma patients. Clin Chem Lab Med 2008;46:836-41.
• Ogawa F, Shimizu K, Hara T, Muroi E, Hasegawa M, Takehara K, Sato S. Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: association with fibrosis and vascular damage. Clin Exp Rheumatol 2008;26:659-62.
• Ogawa F, Shimizu K, Hara T, Muroi E, Hasegawa M, Takehara K, Sato S. Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: association with fibrosis and vascular damage. Clin Exp Rheumatol 2008;26:659-62.
• Devrim E, Erten S, Erguder IB, Namuslu M, Turgay M, Durak I. Malondialdehyde and nitric oxide levels in erythrocytes from patients with systemic sclerosis. Med Princ Pract 2008;17:349-50.
• Tufvesson E, Bozovic G, Hesselstrand R, Bjermer L, Scheja A, Wuttge DM. Increased cysteinyl- leukotrienes and 8-isoprostane in exhaled breath condensate from systemic sclerosis patients. Rheumatology (Oxford). 2010;49(12):2322-6.
• Ogawa F, Shimizu K, Muroi E, Hara T, Sato S. Increasing levels of serum antioxidant status, total antioxidant power, in systemic sclerosis. Clin Rheumatol 2011;30:921-5. YAZIÞMA ADRESÝ
• Uzm. Dr. Þükran ERTEN
• Atatürk Eðitim ve Araþtýrma Hastanesi Romatoloji
• Bölümü, ANKARA, TÜRKÝYE
• E-Posta : [e-mail] Geliþ Tarihi Kabul Tarihi : 14.11.2011